{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:07:13Z","timestamp":1779246433234,"version":"3.51.4"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119222","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:21:22Z","timestamp":1773930082000},"page":"119222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting NLRP3 inflammasome signaling for atrial fibrillation therapy"],"prefix":"10.1016","volume":"198","author":[{"given":"Yuhang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiye","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linhui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-365X","authenticated-orcid":false,"given":"Wenchao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.biopha.2026.119222_bib1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.116.022388","article-title":"National trends in atrial fibrillation hospitalization, readmission, and mortality for medicare beneficiaries, 1999-2013","volume":"135","author":"Freeman","year":"2017","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.biopha.2026.119222_bib2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119222_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980\u20132000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.biopha.2026.119222_bib4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ. Res"},{"issue":"5","key":"10.1016\/j.biopha.2026.119222_bib5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCRESAHA.117.311081","article-title":"Translational challenges in atrial fibrillation","volume":"122","author":"Heijman","year":"2018","journal-title":"Circ. Res"},{"issue":"4","key":"10.1016\/j.biopha.2026.119222_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrcardio.2015.2","article-title":"Inflammation and the pathogenesis of atrial fibrillation","volume":"12","author":"Hu","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"issue":"23","key":"10.1016\/j.biopha.2026.119222_bib7","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jacc.2022.03.379","article-title":"Inflammasome signaling in atrial fibrillation: JACC state-of-the-art review","volume":"79","author":"Ajoolabady","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119222_bib8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41569-018-0045-5","article-title":"Inflammasome activation in AF","volume":"15","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib9","first-page":"589","article-title":"NLRP3 inflammasome: a potential target for predicting arrhythmia recurrence after atrial fibrillation ablation","volume":"65","author":"Han","year":"2022","journal-title":"J. Inter. Card. Electro"},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jacbts.2021.08.006","article-title":"Targeting the inflammasome in cardiovascular disease","volume":"7","author":"Olsen","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ctm2.13","article-title":"NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases","volume":"10","author":"Wang","year":"2020","journal-title":"Clin. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2026.119222_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41574-024-01047-y","article-title":"Inflammation and resolution in obesity","volume":"21","author":"Sot\u00e1k","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41569-022-00759-w","article-title":"Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology","volume":"20","author":"Dobrev","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119222_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00395-016-0584-z","article-title":"Cross-talk between macrophages and atrial myocytes in atrial fibrillation","volume":"111","author":"Sun","year":"2016","journal-title":"Basic Res Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.amjcard.2018.09.017","article-title":"Predictors, burden, and the impact of arrhythmia on patients admitted for acute myocarditis","volume":"123","author":"Adegbala","year":"2019","journal-title":"Am. J. Cardiol."},{"issue":"20","key":"10.1016\/j.biopha.2026.119222_bib17","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1001\/jama.2011.1615","article-title":"Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis","volume":"306","author":"Walkey","year":"2011","journal-title":"Jama"},{"issue":"19","key":"10.1016\/j.biopha.2026.119222_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167517","article-title":"Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation","volume":"133","author":"Song","year":"2023","journal-title":"J. Clin. Invest"},{"issue":"20","key":"10.1016\/j.biopha.2026.119222_bib19","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119222_bib20","article-title":"Fibroblast-specific inflammasome activation predisposes to atrial fibrillation","author":"Li","year":"2023","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imr.12908","article-title":"Therapeutic modulation of inflammasome pathways","volume":"297","author":"Chauhan","year":"2020","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s43556-024-00179-x","article-title":"NLRP inflammasomes in health and disease","volume":"5","author":"Xu","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.biopha.2026.119222_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharm. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2026.119222_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002755","article-title":"Expression analysis of the NLRP gene family suggests a role in human preimplantation development","volume":"3","author":"Zhang","year":"2008","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.biopha.2026.119222_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn7583","article-title":"Directionality of PYD filament growth determined by the transition of NLRP3 nucleation seeds to ASC elongation","volume":"8","author":"Hochheiser","year":"2022","journal-title":"Sci. Adv."},{"issue":"7944","key":"10.1016\/j.biopha.2026.119222_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41586-022-05570-8","article-title":"Cryo-EM structures of the active NLRP3 inflammasome disc","volume":"613","author":"Xiao","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41590-025-02088-9","article-title":"Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants","volume":"26","author":"Feng","year":"2025","journal-title":"Nat. Immunol."},{"issue":"7856","key":"10.1016\/j.biopha.2026.119222_bib28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41586-021-03320-w","article-title":"Structural and biochemical mechanisms of NLRP1 inhibition by DPP9","volume":"592","author":"Huang","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2026.119222_bib29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"24","key":"10.1016\/j.biopha.2026.119222_bib30","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1016\/j.molcel.2023.11.015","article-title":"ZDHHC5-mediated NLRP3 palmitoylation promotes NLRP3-NEK7 interaction and inflammasome activation","volume":"83","author":"Zheng","year":"2023","journal-title":"Mol. Cell"},{"issue":"7904","key":"10.1016\/j.biopha.2026.119222_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41586-022-04467-w","article-title":"Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3","volume":"604","author":"Hochheiser","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3899\/jrheum.130310","article-title":"Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus","volume":"41","author":"Yang","year":"2014","journal-title":"J. Rheuma"},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12974-019-1670-6","article-title":"Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson's disease","volume":"17","author":"Fan","year":"2020","journal-title":"J. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.biopha.2026.119222_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1692","article-title":"Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3\/GSDMD-mediated pyroptosis in colorectal cancer","volume":"14","author":"Guan","year":"2024","journal-title":"Clin. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2026.119222_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119222_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015513","article-title":"Novel role for tranilast in regulating NLRP3 ubiquitination, vascular inflammation, and atherosclerosis","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2026.119222_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu Rev. Immunol."},{"issue":"40","key":"10.1016\/j.biopha.2026.119222_bib38","doi-asserted-by":"crossref","first-page":"10642","DOI":"10.1073\/pnas.1708194114","article-title":"Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis","volume":"114","author":"Kuang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.biopha.2026.119222_bib39","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1365-2443.2004.00789.x","article-title":"ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules","volume":"9","author":"Yamamoto","year":"2004","journal-title":"Genes Cells"},{"issue":"7521","key":"10.1016\/j.biopha.2026.119222_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature13683","article-title":"Inflammatory caspases are innate immune receptors for intracellular LPS","volume":"514","author":"Shi","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2026.119222_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108998","article-title":"Gasdermin E permits interleukin-1 beta release in distinct sublytic and pyroptotic phases","volume":"35","author":"Zhou","year":"2021","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.biopha.2026.119222_bib42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2016.01.012","article-title":"Human monocytes engage an alternative inflammasome pathway","volume":"44","author":"Gaidt","year":"2016","journal-title":"Immunity"},{"issue":"23","key":"10.1016\/j.biopha.2026.119222_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25235533","article-title":"Inhibiting the NLRP3 inflammasome","volume":"25","author":"El-Sharkawy","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","article-title":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets","volume":"23","author":"Vande Walle","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.biopha.2026.119222_bib45","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119222_bib46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cytogfr.2021.09.001","article-title":"The role and transformative potential of IL-19 in atherosclerosis","volume":"62","author":"Chen","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.biopha.2026.119222_bib47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/cpdd.1162","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral NLRP3 inflammasome inhibitor ZYIL1: first-in-human phase 1 studies (single ascending dose and multiple ascending dose)","volume":"12","author":"Parmar","year":"2023","journal-title":"Clin. Pharm. Drug Dev."},{"key":"10.1016\/j.biopha.2026.119222_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175610","article-title":"VX-765 ameliorates CKD VSMC calcification by regulating STAT3 activation","volume":"945","author":"Duan","year":"2023","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119222_bib49","unstructured":"ZOMAGEN BIOSCIENCES LTD. N-((1,2,3,5,6,7-hexahydro-s-indacen-4-YL)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS).WO2021009566A1(2021)."},{"key":"10.1016\/j.biopha.2026.119222_bib50","unstructured":"VENTUS THERAPEUTICS U.S, INC. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives.US11618751B1(2023)."},{"issue":"21","key":"10.1016\/j.biopha.2026.119222_bib51","doi-asserted-by":"crossref","first-page":"14897","DOI":"10.1021\/acs.jmedchem.3c01398","article-title":"Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders","volume":"66","author":"Harrison","year":"2023","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-021-00537-z","article-title":"Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-\u03b2 induced retinal pigmented epithelium degeneration","volume":"6","author":"Narendran","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2026.119222_bib53","unstructured":"HALIA THERAPEUTICS, INC.Heterocyclic compounds, such as HT-6184, for use in the treatment of pain.WO2025160453A1 (2025)."},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib54","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1124\/jpet.123.002013","article-title":"Reversal of high fat diet-induced obesity, systemic inflammation, and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796","volume":"388","author":"Thornton","year":"2024","journal-title":"J. Pharm. Exp. Ther."},{"issue":"14","key":"10.1016\/j.biopha.2026.119222_bib55","doi-asserted-by":"crossref","first-page":"14195","DOI":"10.1021\/acs.jmedchem.5c00781","article-title":"Discovery of AZD4144, a selective and potent NLRP3 inhibitor for the treatment of inflammatory diseases","volume":"68","author":"Johansson","year":"2025","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2026.119222_bib56","unstructured":"HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD.Novel NLRP3 inflammasome inhibitors.WO2024041460A1(2024)."},{"key":"10.1016\/j.biopha.2026.119222_bib57","unstructured":"Akros Pharma. \u3008https:\/\/www.akrospharma.com\/\u3009, (accessed 13 November 2025)."},{"issue":"11","key":"10.1016\/j.biopha.2026.119222_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1471","article-title":"A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis","volume":"13","author":"Klughammer","year":"2023","journal-title":"Clin. Transl. Med"},{"issue":"788","key":"10.1016\/j.biopha.2026.119222_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado0020","article-title":"Targeting GOLPH3L improves glioblastoma radiotherapy by regulating STING-NLRP3-mediated tumor immune microenvironment reprogramming","volume":"17","author":"Sun","year":"2025","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2026.119222_bib60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejmech.2016.06.015","article-title":"Discovery and development of natural product oridonin-inspired anticancer agents","volume":"122","author":"Ding","year":"2016","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2026.119222_bib61","unstructured":"Monte Rosa Therapeutics.Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases.\u3008https:\/\/www.monterosatx.com\/\u3009, (accessed 13 November 2025)."},{"issue":"20","key":"10.1016\/j.biopha.2026.119222_bib62","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14712598.2022.2005024","article-title":"Rilonacept for the treatment of recurrent pericarditis","volume":"22","author":"Fava","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2026.119222_bib64","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","article-title":"Anakinra for the treatment of rheumatoid arthritis: a safety evaluation","volume":"17","author":"Ram\u00edrez","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: in-depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.biopha.2026.119222_bib66","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","article-title":"FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation","volume":"21","author":"Hu","year":"2020","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119222_bib67","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12265-020-09965-8","article-title":"Role of NLRP3-inflammasome\/caspase-1\/galectin-3 pathway on atrial remodeling in diabetic rabbits","volume":"13","author":"Wu","year":"2020","journal-title":"J. Cardiovasc Transl. Res"},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib68","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med"},{"issue":"6","key":"10.1016\/j.biopha.2026.119222_bib69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119222_bib70","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","article-title":"Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation","volume":"197","author":"Primiano","year":"2016","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib71","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cvr\/cvab114","article-title":"Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome","volume":"118","author":"Zhang","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"21","key":"10.1016\/j.biopha.2026.119222_bib72","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1021\/acs.jmedchem.2c01250","article-title":"Overcoming preclinical safety obstacles to discover (S)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): a potent and selective nlrp3 inhibitor","volume":"65","author":"McBride","year":"2022","journal-title":"J. Med Chem."},{"issue":"5","key":"10.1016\/j.biopha.2026.119222_bib73","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1021\/acs.jmedchem.4c02759","article-title":"Discovery of DFV890, a potent sulfonimidamide-containing NLRP3 inflammasome inhibitor","volume":"68","author":"Shen","year":"2025","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib74","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"issue":"ement1","key":"10.1016\/j.biopha.2026.119222_bib75","article-title":"HT-6184 inhibits the formation of the NLRP3 inflammasome in human monocytic THP-1 cells","volume":"142","author":"Bearss","year":"2023","journal-title":"Blood"},{"issue":"6212","key":"10.1016\/j.biopha.2026.119222_bib76","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1261754","article-title":"Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity","volume":"346","author":"Fowler","year":"2014","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.biopha.2026.119222_bib77","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"C.T. group, antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.biopha.2026.119222_bib78","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.008197","article-title":"Canakinumab after electrical cardioversion in patients with persistent atrial fibrillation: a pilot randomized trial","volume":"13","author":"Krisai","year":"2020","journal-title":"Circ. Arrhythm. Electro"},{"issue":"20","key":"10.1016\/j.biopha.2026.119222_bib79","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023252","article-title":"Interleukin-1 trap rilonacept improved health-related quality of life and sleep in patients with recurrent pericarditis: results from the phase 3 clinical trial RHAPSODY","volume":"11","author":"Brucato","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"20","key":"10.1016\/j.biopha.2026.119222_bib80","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.biopha.2026.119222_bib81","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1161\/CIRCULATIONAHA.111.026153","article-title":"Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy","volume":"124","author":"Imazio","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.biopha.2026.119222_bib82","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad169","article-title":"Safety and efficacy of colchicine for the prevention of post-operative atrial fibrillation in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials","volume":"25","author":"Agarwal","year":"2023","journal-title":"Europace"},{"issue":"20","key":"10.1016\/j.biopha.2026.119222_bib83","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2013.08.726","article-title":"Colchicine and the heart: pushing the envelope","volume":"62","author":"Deftereos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2026.119222_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110384","article-title":"Colchicine prevents atrial fibrillation promotion by inhibiting IL-1beta-induced IL-6 release and atrial fibrosis in the rat sterile pericarditis model","volume":"129","author":"Wu","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib85","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.123.012387","article-title":"Colchicine to prevent atrial fibrillation recurrence after catheter ablation: a randomized, placebo-controlled trial","volume":"17","author":"Benz","year":"2024","journal-title":"Circ. Arrhythm. Electro"},{"issue":"10413","key":"10.1016\/j.biopha.2026.119222_bib86","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(23)01689-6","article-title":"C.-A. Investigators, effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial","volume":"402","author":"Conen","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.biopha.2026.119222_bib87","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s40265-014-0324-3","article-title":"Dapagliflozin: a review of its use in patients with type 2 diabetes","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs"},{"issue":"6116","key":"10.1016\/j.biopha.2026.119222_bib88","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib89","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose Co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib92","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2026.119222_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155159","article-title":"Helenine blocks NLRP3 activation by disrupting the NEK7-NLRP3 interaction and ameliorates inflammatory diseases","volume":"122","author":"Fang","year":"2024","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.biopha.2026.119222_bib94","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202153499","article-title":"Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction","volume":"23","author":"Li","year":"2022","journal-title":"EMBO Rep."},{"issue":"8","key":"10.1016\/j.biopha.2026.119222_bib95","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1002\/ptr.7514","article-title":"Polysaccharide extract from Isatidis Radix inhibits multiple inflammasomes activation and alleviate gouty arthritis","volume":"36","author":"Ren","year":"2022","journal-title":"Phytother. Res"},{"key":"10.1016\/j.biopha.2026.119222_bib96","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors","volume":"13","author":"Zhan","year":"2022","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119222_bib97","article-title":"Targeted protein degradation bypassing cereblon and von Hippel-Lindau","volume":"4","author":"Lu","year":"2023","journal-title":"Innov. (Camb. )"},{"issue":"5","key":"10.1016\/j.biopha.2026.119222_bib98","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.RES.0000260203.55077.61","article-title":"A role for caspase-1 in heart failure","volume":"100","author":"Merkle","year":"2007","journal-title":"Circ. Res"},{"key":"10.1016\/j.biopha.2026.119222_bib99","doi-asserted-by":"crossref","unstructured":"W. Wannamaker, R. Davies, M. Namchuk, J. Pollard, P. Ford, G. Ku, C. Decker, P. Charifson, P. Weber, U.A. Germann, K. Kuida, J.C. Randle, (S)-1-((S)-2-[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18, J Pharmacol Exp Ther 321(2) (2007) 509-516.","DOI":"10.1124\/jpet.106.111344"},{"issue":"2","key":"10.1016\/j.biopha.2026.119222_bib100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10557-018-6781-2","article-title":"The caspase 1 inhibitor VX-765 protects the isolated rat heart via the RISK pathway","volume":"32","author":"Do Carmo","year":"2018","journal-title":"Cardiovasc Drugs Ther."},{"issue":"26","key":"10.1016\/j.biopha.2026.119222_bib101","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1722041115","article-title":"Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis","volume":"115","author":"McKenzie","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7610","key":"10.1016\/j.biopha.2026.119222_bib102","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature18590","article-title":"Pore-forming activity and structural autoinhibition of the gasdermin family","volume":"535","author":"Ding","year":"2016","journal-title":"Nature"},{"issue":"7610","key":"10.1016\/j.biopha.2026.119222_bib103","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2026.119222_bib104","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.biopha.2026.119222_bib105","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/CIRCRESAHA.114.303211","article-title":"The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms","volume":"114","author":"Andrade","year":"2014","journal-title":"Circ. Res"},{"issue":"9","key":"10.1016\/j.biopha.2026.119222_bib106","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCRESAHA.114.302226","article-title":"Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression","volume":"114","author":"Heijman","year":"2014","journal-title":"Circ. Res"},{"issue":"20","key":"10.1016\/j.biopha.2026.119222_bib107","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119222_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97054","article-title":"CaMKII\u03b4-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis","volume":"3","author":"Willeford","year":"2018","journal-title":"JCI Insight"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:32:26Z","timestamp":1779244346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":108,"alternative-id":["S0753332226002556"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119222","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting NLRP3 inflammasome signaling for atrial fibrillation therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119222"}}